| 1 | Comparative IgG responses to SARS-CoV-2 after natural infection or vaccination |
|----|--|
| 2 | |
| 3 | Kaylan M. Olds, MS, ¹ Devon P. Humphreys, MA, ¹ Kathleen M. Gavin, PhD, ^{1,2} Anne L. Wyllie, |
| 4 | PhD ³ and Timothy A. Bauer, PhD ^{1,2*} |
| 5 | ¹ Everly Health, Inc., 823 Congress Ave, STE 1200, Austin TX 78701 |
| 6 | ² University of Colorado Anschutz Medical Campus, Aurora, CO 80045 |
| 7 | ³ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New |
| 8 | Haven, CT 06510 |
| 9 | *Corresponding Author |
| 10 | |
| 11 | Address for correspondence: |
| 12 | Timothy Bauer, PhD, Everly Health, Inc., 823 Congress Ave., Suite 1200, Austin, TX 78701; |
| 13 | phone: 303-503-5713; email: tbauer@everlyhealth.com |
| 14 | |
| 15 | Keywords: |
| 16 | COVID-19; humans; adults; immunity; seroprevalence; antibody durability; dried blood spot |
| 17 | |
| 18 | |
| 19 | |

20 Abstract

| 21 | Background: Whether vaccination or natural infection provides greater benefit regarding the |
|----|---|
| 22 | development of sustained immunity against SARS-CoV-2 remains unknown. Therefore, the aim |
| 23 | of this study was to provide a direct comparison of IgG durability in vaccinated and |
| 24 | unvaccinated adults. |
| 25 | Methods: This was a prospective, cross-sectional study of antibody durability in 1087 individuals |
| 26 | with a median (IQR) age of 42 (35, 52) years who were unvaccinated and previously infected |
| 27 | with SARS-CoV-2 (Arm 1, n=351) or vaccinated against the virus (Arm 2, n=737). Participants |
| 28 | self-reported vaccination and infection history and provided self-collected serology samples |
| 29 | using mailed collection kits. |
| 30 | Results: Anti-S1 IgG seroprevalence was 15.6% higher in vaccinated versus unvaccinated, |
| 31 | previously-infected individuals across intervals ranging from 1 to 12 months and antibody |
| 32 | survival was sustained near 100% through 12 months in the vaccinated group. |
| 33 | Conclusions: These findings suggest that vaccination as opposed to natural infection alone |
| 34 | provides significant advantages in terms of sustained and effective immunity against prior |
| 35 | variants of SARS-CoV-2. Future efforts to characterize SARS-CoV-2 immune responses should |
| 36 | address hybrid immunity, booster status and formulation, and protection against (sub)variants of |
| 37 | Omicron and future lineages, as well as weigh the potential impact of other immune system |
| 38 | mechanisms. |
| 39 | |
| 40 | |
| 41 | |

43 Introduction

| 44 | Throughout the course of the Coronavirus Disease 2019 (COVID-19) pandemic, the widespread |
|----|--|
| 45 | adoption of vaccination has been promoted for its potential to significantly curtail health and |
| 46 | economic burdens related to the spread of SARS-CoV-2, and ultimately, key to bringing the |
| 47 | pandemic to an end (1, 2). In less than a year from the World Health Organization (WHO) |
| 48 | declaring the pandemic, following an unprecedented development effort, vaccines were available |
| 49 | to most adults in western societies. However, vaccination campaigns were met with varying |
| 50 | degrees of hesitancy in portions of the population (3-5). In the intervening months, researchers |
| 51 | documented Immunoglobulin G (IgG) seroconversion and fluctuating levels of sustained |
| 52 | immunity resulting from natural infection and/or vaccination (6-15), and established a positive |
| 53 | relationship between anti-spike antibodies and clinical protection from SARS-CoV-2 (16-18). |
| 54 | |
| 55 | However, the current literature does not provide a clear difference in antibody profiles acquired |
| 56 | through vaccination and natural infection. This distinction is of renewed importance at a time |
| 57 | when nearly 60% of the United States (US) population (including 75% of US children) are |
| 58 | reported to show serological evidence of community exposure (19) and the sense of urgency |
| 59 | related to vaccination has waned. Despite a growing body of literature, availability of data |
| 60 | directly comparing antibody responses following vaccination versus natural infection is limited. |
| 61 | Prospective evaluations tend to be limited in sample size (12, 14, 20-22), have short serological |
| 62 | monitoring periods, (9, 20, 22) or analyses were completed retrospectively (23, 24). Many studies |
| 63 | utilize populations of healthcare workers who may encounter infectious agents - including |
| 64 | SARS-CoV-2 – more frequently than other members of the community, limiting generalizability |
| 65 | of results due to potential repeated exposures and subclinical infections (9, 12, 20, 25). Several |

| 66 | quality studies have evaluated the effectiveness of vaccination- and/or infection-acquired |
|----|---|
| 67 | immunity over time, but have lacked a serological component (24-26). Therefore, in the current |
| 68 | study, we aimed to provide a direct comparison of IgG durability in vaccinated and unvaccinated |
| 69 | individuals in a prospective US sample. This work presents the largest such comparison in a |
| 70 | prospectively-collected, population-wide sample to date. |
| 71 | |
| 72 | Methods |
| 73 | Ethics approval and consent to participate |
| 74 | This protocol was approved by WCG IRB (IRB registration #20210763). All participants |
| 75 | provided written informed consent prior to enrollment in the study. |
| 76 | |
| 77 | Study design |
| 78 | This was a prospective, cross-sectional study of antibody durability in individuals who were |
| 79 | previously infected with SARS-CoV-2 (Arm 1) or vaccinated against the virus (Arm 2). The |
| 80 | study utilized electronic questionnaires and self-collected dried blood spot (DBS) samples to |
| 81 | gather data remotely from participants within the US. Upon enrollment, participants answered |
| 82 | questions about COVID-19 diagnosis and vaccination history, symptom and treatment |
| 83 | information, and other relevant medical history such as comorbid conditions and medication use. |
| 84 | Participants received a COVID-19 Antibody Home Collection Kit (Everlywell, Inc., Austin, TX) |
| 85 | to provide samples for qualitative IgG detection. Baseline data were captured to complete the |
| 86 | primary analysis of comparative IgG durability between study arms. In addition, Arm 2 |
| 87 | participants repeated questionnaires and serology tests during a follow-up period for up to 9 |
| 88 | months, facilitating a secondary survival analysis of vaccine-acquired IgG. |

89

90 Participant eligibility and enrollment

| 91 | Participants were enrolled in the study between March and November 2021. Inclusion criteria for |
|-----|--|
| 92 | Arm 1 included prior infection with SARS-CoV-2 (evidenced by a positive diagnostic test) and |
| 93 | unvaccinated status. Eligibility for Arm 2 required receipt of at least one dose of a SARS-CoV-2 |
| 94 | vaccine. All participants were required to be age 18 years or older, reside within the continental |
| 95 | US, and have access to an email account and internet service. Exclusion criteria included known |
| 96 | conditions or ongoing treatments associated with immune impairment (e.g., chemotherapy) and |
| 97 | residents of New York state. All participants provided written informed consent prior to |
| 98 | enrollment in the study, which was approved by WCG IRB (IRB study #20210763). |
| 99 | |
| 100 | Serology Testing |
| 101 | DBS samples were self-collected at baseline and follow-up timepoints for serology testing using |
| 102 | the Anti-SARS-CoV-2 ELISA Assay (EUROIMMUN, Germany). |
| 103 | |
| 104 | Study Endpoints |
| 105 | The primary endpoint was the expected difference in S1-binding IgG seropositivity between Arm |
| 106 | 1 (unvaccinated, naturally infected individuals) and Arm 2 (vaccinated individuals) over |
| 107 | time. The secondary endpoints included: S1-binding IgG survival percentages at 4 and 12 |
| 108 | months since last exposure to a vaccine product in Arm 2. |
| 109 | |
| 110 | Statistical Analysis |

111 Multiple linear regression was used to evaluate the effect size and significance of each study arm 112 (vaccination vs natural infection) on estimated seropositivity over time (binned as the number of 113 months since last vaccine dose or infection). Estimates per study arm per time interval that 114 included fewer than 3 serology values were considered under sampled and dropped prior to 115 analysis. 116 117 Additionally, a discrete-time analysis was conducted using independent z-tests of proportions at 118 1, 3, 6, 9, and 12 months to evaluate differences in seropositivity between Arms 1 and 2. P-119 values are reported and interpretable using a Bonferroni-adjusted value of 0.005. To further 120 evaluate S1-binding IgG durability associated with vaccination, survival analysis was performed 121 using the Kaplan-Meier method. Percent survival at 4 and 12 months is reported with 95% 122 confidence intervals. This analysis was conducted in two ways, reflecting (1) time from the most

recent vaccination dose (i.e., a booster dose reset the interval clock), and (2) time from the initial

124 vaccination dose.

125

126 **Results**

127 S1-binding IgG Cross-Sectional Analysis

128 A total of 1,087 participants enrolled in the study and completed all required baseline

assessments for inclusion in the analysis: 351 were assigned to Arm 1 and 737 were assigned to

130 Arm 2 at baseline. Over three quarters of participants included in the cross-sectional analysis

131 were female, and the median (IQR) age was 42 (35, 52) years. Over two thirds of vaccinated

132 participants reported no previous SARS-CoV-2 infection prior to entering the study. Baseline

133 participant characteristics are summarized in Table 1.

134

| | Overall | Arm 1 | Arm 2 | |
|---------------------------------|-------------|-------------|-------------|--|
| Characteristic | N = 1088 | N = 351 | N = 737 | |
| Sex | | | | |
| Female | 831 (76%) | 258 (74%) | 573 (78%) | |
| Male | 255 (23%) | 93 (26%) | 162 (22%) | |
| Unknown | 2 (0.2%) | 0 (0%) | 2 (0.3%) | |
| Age | | | | |
| Median (IQR) | 42 (35, 52) | 43 (34, 54) | 42 (35, 51) | |
| Unknown | 2 (0.2%) | 0 (0%) | 2 (0.3%) | |
| COVID Diagnostic History | | | | |
| Known Infection | 566 (52%) | 351 (100%) | 215 (29%) | |
| No Known Infection | 508 (47%) | 0 (0%) | 508 (69%) | |
| Unknown/NA | 14 (1.3%) | 0 (0%) | 14 (1.9%) | |
| Vaccine Product | | | | |
| Ad26.COV2.s (Johnson & | 56 (5.1%) | 0 (0%) | 56 (7.6%) | |
| Johnson) | | | | |
| BNT162b2 (Pfizer) | 396 (36%) | 0 (0%) | 396 (54%) | |
| mRNA-1273 (Moderna) | 280 (26%) | 0 (0%) | 280 (38%) | |
| NVX-CoV2373 (Novavax) | 1 (<0.1%) | 0 (0%) | 1 (0.1%) | |
| Not Applicable | 351 (32%) | 351 (100%) | 0 (0%) | |
| Unknown | 4 (0.4%) | 0 (0%) | 4 (0.5%) | |

135 Table 1: Participant demographics and diagnostic test history

136

137

Nearly all Arm 2 participants entered the study fully vaccinated, defined as having received all
doses in the primary series of the applicable vaccine, with only 3.7% reporting partial
vaccination (or only having received one dose of a two-dose primary vaccination regimen) at
baseline. No participants reported receiving a booster dose prior to enrollment. The difference in
time between participants' most recent confirmed exposure (positive diagnostic test date or
vaccination date for Arm 1 or 2, respectively) and baseline serology test date ranged from 1 to 15
months (median) after dropping under-sampled time intervals (N=1,007).

- 146 Population-wide seropositivity remained high across time intervals. The seropositivity effect size
- 147 associated with vaccination was 15.6% greater than the reference arm (Arm 1), independent of
- time since vaccination (Figure 1 and Table 2).
- 149
- 150 Table 2: Difference in seropositivity by exposure mode

| Time Interval | Difference in Arm 2 (Vaccinated) versus Arm 1 (Unvaccinated/Natural Infection) | Z-score | p-value |
|------------------|---|---------|-------------------------|
| 1 month | +11.9% | -28.06 | 1.37×10^{-173} |
| 3 months | +14.3% | -125.62 | 0.00 |
| 6 months | +15.6% | -66.93 | 0.00 |
| 9 months | +13.5% | -13.58 | 2.71×10^{-42} |
| 12 months | +11.1% | -4.33 | 7.34x10 ⁻⁶ |

151

152 *S1-binding IgG Longitudinal Analysis in vaccinated individuals (Arm 2)*

153 A total of 1,605 samples from 737 vaccinated individuals were available for antibody survival

analysis. Antibody survival (with 95% CI) ranged from 99.4% (99.0%-100%) at 4 months to

155 95.5% (91.7%-99.5%) at 12 months when measured in time since the last dose received, and

156 from 99.7% (99.3% - 100%) at 4 months to 98.4% (97.1%-99.7%) at 12 months when measured

157 from the first dose. No further loss of IgG detectability was observed beyond 12 months in either

analysis.

159

160 Discussion

161 This study aimed to provide the first direct comparison of IgG durability in vaccinated and

162 unvaccinated individuals in a large, prospective, population-wide US sample. Both vaccination

against COVID-19 and natural infection with SARS-CoV-2 are associated with seroconversion

in most people. However, we found IgG seropositivity was significantly higher, more consistent,

165 and declined less rapidly in vaccinated individuals than in those who were unvaccinated and 166 previously infected with the virus. This pattern was evident one-month post-exposure (the 167 earliest time interval evaluated) and persisted through 12 months post infection or most recent 168 vaccination dose. One possible explanation for the discrepancy between vaccinated and naturally 169 infected groups could be the controlled dose of target antigen provided (indirectly, in many 170 cases) through vaccination, versus the inconsistent "dose" of various viral antigens acquired 171 through natural infection. In a within-subject survival analysis, vaccine-acquired IgG antibodies 172 persisted for up to 12 months (or more) in nearly all cases. This provides within-subject support 173 for strong antibody durability out to 12 months when compared to the vaccinated group (Arm 2) 174 in the cross-sectional analysis. Collectively, these analyses suggest that IgG antibodies raised 175 through vaccination are more reliably durable than those induced by a natural SARS-CoV-2 176 infection in most individuals.

177

178 Compared to prior research, our estimated rate of seropositivity decline in the unvaccinated 179 group was steeper. Alfego et al. found seropositivity decline to be approximately -0.004% per 180 day, or approximately -0.12% per month (11), while we observed a decline of -0.93% per month. 181 This may be reflective of our smaller sample size or due to an important distinction between each 182 studies' methods. Alfego et al. evaluated seropositivity from the time of a participant's first 183 recorded infection (positive diagnostic test) and did not take subsequent exposure events into 184 account, whereas in the current study, we measured seropositivity from the time of the most 185 recent confirmed infection. Nevertheless, the rate of seropositivity decline in the vaccinated 186 cohort was much lower than in the unvaccinated cohort. This holds true whether we compare this 187 rate to those estimates from Alfego et al. or to our own rate estimates for Arm 1 in the present

study. Collectively, this suggests that S-protein antibodies raised through vaccination are more
reliably durable than those induced by a natural SARS-CoV-2 infection in most individuals.

191 While neutralizing antibody (NAb) titer is a closer surrogate for immune protection, Anti-S IgG 192 testing offers an advantage in scalability as the requisite immunoassays are less burdensome in 193 terms of time, cost, complexity, and availability than functional NAb assays. Published works 194 by Harvala et al. and Lumley et al. lend support to the clinical relevance of IgG values. The 195 former reported that detection of IgG with the Euroimmun assay highly correlated with NAb 196 titers above 1:100 in convalescent blood samples (27), while the latter observed a connection 197 between S-binding IgG and protection from reinfection with earlier variants of SARS-CoV-2 in 198 previously-infected healthcare professionals followed up to 6 months (18).

199

200 Given the correlation of IgG levels with NAb titers and that NAb concentration correlates with 201 protection against infection and severe disease (16, 17), our observations suggest that vaccine-202 acquired immunity may also be more protective than an immune response triggered by natural 203 infection alone. Our findings support similar observations made in Congolese individuals at 2 204 months post vaccination (with Ad26.COV.2 or BBIP-CorV) compared to 2, 3, or 6 months post 205 natural infection (21). However, whether a vaccine-induced IgG response provides an advantage 206 over the longer term remains unclear. For example, in a previous evaluation of purely vaccine-207 induced NAb activity in 62 healthcare workers, which excluded cases of prior exposures or 208 breakthrough infections, Decru et al. found significant waning of neutralization activity 10 209 months after receiving a second dose of BNT162b2 (12). If NAb follows similar patterns as anti-210 S IgG, it may be that hybrid immunity provides the most durable NAb response. More research

is needed to clarify which approach produces the longest enduring neutralization capability.
Furthermore, the limitation remains that without more prevailing use of a common reference
standard it is difficult to determine what level of titer is necessary for protection, whether that
involves full immunity or simply protection from severe disease. In addition, the contribution of
other immune factors (e.g., IgA and mucosal immunity) on overall protection should not be
overlooked, especially considering those responses may follow different patterns than IgG after
vaccination or natural infection.

218

219 One problem that warrants further study is the impact of symptom severity on antibody 220 responses in previously-infected individuals who become vaccinated (hybrid immunity) 221 compared to those who remain unvaccinated, given that binding IgG and NAb responses during 222 and after severe disease are higher functioning and longer lasting than when symptoms are mild 223 (28-30). Future research may also look at the relationships between viral variants and population-224 wide antibody profiles in vaccinated and unvaccinated cohorts, as well as how antibody 225 characteristics connect to clinical outcomes and transmissibility in each group. Moreover, 226 additional focus should be paid to hybrid immunity and the impact of repeated (or breakthrough) 227 infections and boosters, including extended follow-up (8, 20) for antibody durability and titer 228 beyond one year from each type of exposure in the general population. Flexible study designs 229 that can more easily accommodate adjustments made in response to a rapidly changing viral 230 variant landscape would help future studies maintain relevance over time as SARS-CoV-2 231 transitions from pandemic to endemic circulation.

232

233 Limitations

234 The data for Arm 1 are cross-sectional, therefore individual rates of seroreversion could not be 235 evaluated in direct comparison to Arm 2. Additionally, limited sample sizes at later time 236 intervals reduced statistical confidence in some time-specific point estimates of seropositivity, 237 and limited cases with confirmed hybrid immunity prevented us from evaluating those 238 individuals as a separate group. Furthermore, this study relied on self-reported infection and 239 vaccination history, and only took confirmed exposures (those that resulted in a positive 240 diagnostic test) into account. There is a high likelihood that additional exposures to SARS-CoV-241 2 went undetected and were not reflected in the self-reported COVID-19 diagnostic data; 242 however, we expect that such events would have inflated serology values most frequently in the 243 unvaccinated group. As such, these findings give a conservative estimate of the differences 244 between vaccination and natural infection in terms of antibody response. Finally, our study 245 largely coincided with circulation of the Delta variant, and reflected immune responses triggered 246 by exposure to Alpha, Beta, or Delta variants in previously-infected individuals. The Omicron 247 (BA.1) variant was discovered as this study concluded and has exhibited greater transmissibility 248 than previous variants due to a highly mutated spike protein and consequent immune evasion and 249 increased receptor affinity (31). Subsequent sublineages (BA.1.1, BA.2, BA.3, BA.4, and BA.5) 250 have since been identified and show similar or greater transmissibility and evasion of antibodies 251 compared to the parent variant (32, 33). Furthermore, a new vaccine formulation that offers more 252 protection against Omicron has been made available as a booster dose. It is uncertain how 253 combinations of variant/subvariant exposures and primary/booster vaccine formulations may 254 affect immune responses acquired through natural infection, vaccination, or hybrid exposure in a 255 rapidly shifting landscape that continues to challenge the pace of science.

256

257 Conclusions

| 258 | This study was one of the first to directly compare population-level antibody durability acquired |
|-----|--|
| 259 | through vaccination or natural infection in a nationwide sample and supports the conclusion that |
| 260 | completing the primary series of vaccination triggers a more durable and protective antibody |
| 261 | response compared to a known single infection with early variants of SARS-CoV-2. This study |
| 262 | further supports the importance of broad vaccination campaigns over relying upon natural, |
| 263 | infection-driven herd immunity alone in the fight against SARS-CoV-2. Future work |
| 264 | investigating antibody profiles resultant to booster doses, hybrid immunity, as well as repeat and |
| 265 | variant specific infections are critical in our continued understanding of SARS-CoV-2 and |
| 266 | COVID-19. |
| 267 | |
| 268 | Abbreviations |
| 269 | COVID-19: Coronavirus Disease 2019 |
| 270 | DBS: dried blood spot |
| 271 | IgG: Immunoglobulin G |
| 272 | IQR: Interquartile range |
| 273 | NAb: Neutralizing antibody |
| 274 | US: United States |
| 275 | WHO: World Health Organization |
| 276 | |
| 277 | Declarations |
| 278 | Ethics approval and consent to participate |

- 279 This protocol was approved by WCG IRB (IRB registration #20210763). All participants
- 280 provided written informed consent prior to enrollment in the study.
- 281
- 282 Consent for publication
- 283 Not applicable.
- 284
- 285 Availability of data and materials
- 286 The datasets used and/or analyzed during the current study are available from the corresponding
- author on reasonable request.
- 288
- 289 *Competing interests*
- 290 Kaylan Olds, Devon Humphreys, Kathleen Gavin, and Timothy Bauer are full time employees of
- 291 Everly Health, Inc. Anne Wylie has no conflicts to report.
- 292
- 293 Funding
- 294 This study was funded and conducted by Everly Health, Inc.
- 295

296 Authors' contributions

297 KMO: Had a role in study conception, data interpretation, and drafted the work, DPH: Had a role

in study conception, performed data analysis and interpretation, and assisted in drafting the work,

299 KMG: Performed data interpretation and assisted in drafting the work, ALW: Had a role in data

analysis, data interpretation, and assisted in drafting the work, TAB: Led study conception, data

301 interpretation, and assisted in drafting the work. All authors have reviewed and

302 approved this submitted version of the manuscript.

303

- 304 Acknowledgements
- 305 The authors thank PerkinElmer Genomics, Inc. for providing in-kind support with serology
- 306 testing.
- 307

308 References

- 1. Iboi EA, Ngonghala CN, Gumel AB. Will an imperfect vaccine curtail the COVID-19
- 310 pandemic in the U.S.? Infect Dis Model. 2020;5:510-24.
- 311 2. Shah SMA, Rasheed T, Rizwan K, Bilal M, Iqbal HMN, Rasool N, et al. Risk
- 312 management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. J Infect
- 313 Public Health. 2021;14(3):331-46.
- 314 3. Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang B, et al. Factors
- 315 Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. JAMA Netw
- 316 Open. 2020;3(10):e2025594.
- 317 4. Ball P. Anti-vaccine movement could undermine efforts to end coronavirus pandemic,
 318 researchers warn. Nature. 2020;581(7808):251.
- 319 5. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. National Trends
- in the US Public's Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020.
- 321 JAMA. 2020.
- 322 6. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al.
- 323 Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med.
- 324 2022;386(23):2201-12.

- 325 7. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al.
- 326 Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in
- 327 England. Nat Commun. 2021;12(1):7217.
- 328 8. Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous
- 329 SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
- 330 Lancet. 2021;397(10280):1178-81.
- 331 9. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al.
- 332 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell.
- 333 2021;184(23):5699-714.e11.
- 10. McDade TW, Sancilio A, D'Aquila R, Mustanski B, Vaught LA, Reiser NL, et al. Low
- 335 Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory
- 336 Syndrome Coronavirus 2 in a Community-Based Serological Study. Open Forum Infect Dis.
- 337 2022;9(3):ofac055.
- 338 11. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based
- analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.
- 340 EClinicalMedicine. 2021;36:100902.
- 12. Decru B, Van Elslande J, Steels S, Van Pottelbergh G, Godderis L, Van Holm B, et al.
- 342 IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10
- 343 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare
- 344 Workers. Front Immunol. 2022;13:909910.
- 13. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of
- antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months
- 347 after infection. Nat Microbiol. 2022;7(3):423-33.

| 348 | 14. | Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. |
|-----|-----|--|
|-----|-----|--|

- Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature.
 2021;595(7867):426-31.
- 15. Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et al.
- 352 Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat
- 353 Commun. 2022;13(1):1614.
- 16. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.
- 355 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a
- 356 Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020;58(11).
- 357 17. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
- 358 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
- 359 SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.
- 18. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.
- 361 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J
- 362 Med. 2021;384(6):533-40.
- 363 19. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of
- 364 Infection-Induced SARS-CoV-2 Antibodies United States, September 2021-February 2022.
- 365 MMWR Morb Mortal Wkly Rep. 2022;71(17):606-8.
- 366 20. Arkell P, Gusmao C, Sheridan SL, Tanesi MY, Gomes N, Oakley T, et al. Serological
- 367 surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity
- to SARS-CoV-2 during an outbreak in Dili, Timor-Leste. Int J Infect Dis. 2022;119:80-6.

| 369 | 21. Batchi-Bouyou AL, Djontu JC, Vouvoungui JC, Mfoutou Mapanguy CC, Lobaloba | | | |
|-----|--|----|--|--|
| 370 | Ingoba L, Mougany JS, et al. Assessment of neutralizing antibody responses after natural SAR | S- | | |
| 371 | CoV-2 infection and vaccination in congolese individuals. BMC Infect Dis. 2022;22(1):610. | | | |
| 372 | 22. Bonura F, Genovese D, Amodio E, Calamusa G, Sanfilippo GL, Cacioppo F, et al. | | | |
| 373 | Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior | | | |
| 374 | Infection or mRNA BNT162b2 Vaccination. Vaccines (Basel). 2022;10(6). | | | |
| 375 | 23. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. | | | |
| 376 | Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J | | | |
| 377 | Med. 2022;387(1):21-34. | | | |
| 378 | 24. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, et al. SARS-CoV-2 | | | |
| 379 | Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough | | | |
| 380 | Infections: a Retrospective Cohort Study. Clin Infect Dis. 2022. | | | |
| 381 | 25. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An | | | |
| 382 | Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome | | | |
| 383 | Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers b | уy | | |
| 384 | Antibody and Vaccination Status. Clin Infect Dis. 2022;74(7):1208-19. | | | |
| 385 | 26. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS- | - | | |
| 386 | CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207- | | | |
| 387 | 20. | | | |
| 388 | 27. Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma | | | |
| 389 | therapy for the treatment of patients with COVID-19: Assessment of methods available for | | | |
| 390 | antibody detection and their correlation with neutralising antibody levels. Transfus Med. | | | |
| 391 | 2021;31(3):167-75. | | | |
| | | | | |

| 392 28. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaili J, et al. A longitu | 21tudinal study | 01 |
|--|-----------------|----|
|--|-----------------|----|

- 393 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
- 394 COVID-19 severity. Cell Mol Immunol. 2021;18(2):318-27.
- 395 29. Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
- 396 Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute
- Respiratory Syndrome Coronavirus 2 Infections. J Infect Dis. 2020;222(8):1265-9.
- 398 30. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer
- 399 M, et al. Antibody response to SARS-CoV-2 for more than one year kinetics and persistence of
- 400 detection are predominantly determined by avidity progression and test design. J Clin Virol.
- 401 2022;146:105052.
- 402 31. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al.
- 403 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science.
- 404 2022;375(6583):864-8.
- 405 32. Maxmen A. Why call it BA.2.12.1? A guide to the tangled Omicron family. Nature.
 406 2022;606(7914):446-7.
- 407 33. Yao L, Zhu KL, Jiang XL, Wang XJ, Zhan BD, Gao HX, et al. Omicron subvariants
 408 escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect Dis.
- 409 2022;22(8):1116-7.
- 410
- 411
- 412
- 413
- 414

415 Figure



417 2) groups

